Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en"><sup>90</sup>Y-Edotreotide for Metastatic Carcinoid Refractory to Octreotide</title><author><name sortKey="Bushnell, David L" sort="Bushnell, David L" uniqKey="Bushnell D" first="David L." last="Bushnell">David L. Bushnell</name><affiliation><nlm:aff id="aff1">From the Department of Radiology, Division of Nuclear Medicine, the Department of Internal Medicine, Division of Endocrinology, and Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of Iowa, Roy J. and Lucille A. Carver College of Medicine; Iowa City Veterans Administration Medical Center, Diagnostic Imaging and Radioisotope Therapy Service, Iowa City, IA; Peter MacCallum Cancer Institute, East Melbourne, Victoria, Australia; Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium; Service de Medecine Nucleaire, Paris; Centre de Médecine Nucleaire, Hospices Civils et Université de Lyon; Institut Gustave Roussy, Villejuif, France; Louisiana State University Health Sciences Center, New Orleans, LA; Division of Hematology-Oncology, Northwestern University, Chicago, IL; Medicinkliniken, Endokrin-Oncol, Uppsala, Sweden; Department of Endocrinology, St Bartholomew's Hospital, London, England; Novartis Pharmaceutical Corporation, East Hanover, NJ; Molecular Insight Pharmaceuticals, Cambridge, MA; and Cliniques Universitaires Saint-Luc, Service de Medecine Nucleaire, Brussels, Belgium.</nlm:aff></affiliation></author><author><name sortKey="O Dorisio, Thomas M" sort="O Dorisio, Thomas M" uniqKey="O Dorisio T" first="Thomas M." last="O'Dorisio">Thomas M. O'Dorisio</name><affiliation><nlm:aff id="aff1">From the Department of Radiology, Division of Nuclear Medicine, the Department of Internal Medicine, Division of Endocrinology, and Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of Iowa, Roy J. and Lucille A. Carver College of Medicine; Iowa City Veterans Administration Medical Center, Diagnostic Imaging and Radioisotope Therapy Service, Iowa City, IA; Peter MacCallum Cancer Institute, East Melbourne, Victoria, Australia; Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium; Service de Medecine Nucleaire, Paris; Centre de Médecine Nucleaire, Hospices Civils et Université de Lyon; Institut Gustave Roussy, Villejuif, France; Louisiana State University Health Sciences Center, New Orleans, LA; Division of Hematology-Oncology, Northwestern University, Chicago, IL; Medicinkliniken, Endokrin-Oncol, Uppsala, Sweden; Department of Endocrinology, St Bartholomew's Hospital, London, England; Novartis Pharmaceutical Corporation, East Hanover, NJ; Molecular Insight Pharmaceuticals, Cambridge, MA; and Cliniques Universitaires Saint-Luc, Service de Medecine Nucleaire, Brussels, Belgium.</nlm:aff></affiliation></author><author><name sortKey="O Dorisio, M Sue" sort="O Dorisio, M Sue" uniqKey="O Dorisio M" first="M. Sue" last="O'Dorisio">M. Sue O'Dorisio</name><affiliation><nlm:aff id="aff1">From the Department of Radiology, Division of Nuclear Medicine, the Department of Internal Medicine, Division of Endocrinology, and Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of Iowa, Roy J. and Lucille A. Carver College of Medicine; Iowa City Veterans Administration Medical Center, Diagnostic Imaging and Radioisotope Therapy Service, Iowa City, IA; Peter MacCallum Cancer Institute, East Melbourne, Victoria, Australia; Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium; Service de Medecine Nucleaire, Paris; Centre de Médecine Nucleaire, Hospices Civils et Université de Lyon; Institut Gustave Roussy, Villejuif, France; Louisiana State University Health Sciences Center, New Orleans, LA; Division of Hematology-Oncology, Northwestern University, Chicago, IL; Medicinkliniken, Endokrin-Oncol, Uppsala, Sweden; Department of Endocrinology, St Bartholomew's Hospital, London, England; Novartis Pharmaceutical Corporation, East Hanover, NJ; Molecular Insight Pharmaceuticals, Cambridge, MA; and Cliniques Universitaires Saint-Luc, Service de Medecine Nucleaire, Brussels, Belgium.</nlm:aff></affiliation></author><author><name sortKey="Menda, Yusuf" sort="Menda, Yusuf" uniqKey="Menda Y" first="Yusuf" last="Menda">Yusuf Menda</name><affiliation><nlm:aff id="aff1">From the Department of Radiology, Division of Nuclear Medicine, the Department of Internal Medicine, Division of Endocrinology, and Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of Iowa, Roy J. and Lucille A. Carver College of Medicine; Iowa City Veterans Administration Medical Center, Diagnostic Imaging and Radioisotope Therapy Service, Iowa City, IA; Peter MacCallum Cancer Institute, East Melbourne, Victoria, Australia; Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium; Service de Medecine Nucleaire, Paris; Centre de Médecine Nucleaire, Hospices Civils et Université de Lyon; Institut Gustave Roussy, Villejuif, France; Louisiana State University Health Sciences Center, New Orleans, LA; Division of Hematology-Oncology, Northwestern University, Chicago, IL; Medicinkliniken, Endokrin-Oncol, Uppsala, Sweden; Department of Endocrinology, St Bartholomew's Hospital, London, England; Novartis Pharmaceutical Corporation, East Hanover, NJ; Molecular Insight Pharmaceuticals, Cambridge, MA; and Cliniques Universitaires Saint-Luc, Service de Medecine Nucleaire, Brussels, Belgium.</nlm:aff></affiliation></author><author><name sortKey="Hicks, Rodney J" sort="Hicks, Rodney J" uniqKey="Hicks R" first="Rodney J." last="Hicks">Rodney J. Hicks</name><affiliation><nlm:aff id="aff1">From the Department of Radiology, Division of Nuclear Medicine, the Department of Internal Medicine, Division of Endocrinology, and Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of Iowa, Roy J. and Lucille A. Carver College of Medicine; Iowa City Veterans Administration Medical Center, Diagnostic Imaging and Radioisotope Therapy Service, Iowa City, IA; Peter MacCallum Cancer Institute, East Melbourne, Victoria, Australia; Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium; Service de Medecine Nucleaire, Paris; Centre de Médecine Nucleaire, Hospices Civils et Université de Lyon; Institut Gustave Roussy, Villejuif, France; Louisiana State University Health Sciences Center, New Orleans, LA; Division of Hematology-Oncology, Northwestern University, Chicago, IL; Medicinkliniken, Endokrin-Oncol, Uppsala, Sweden; Department of Endocrinology, St Bartholomew's Hospital, London, England; Novartis Pharmaceutical Corporation, East Hanover, NJ; Molecular Insight Pharmaceuticals, Cambridge, MA; and Cliniques Universitaires Saint-Luc, Service de Medecine Nucleaire, Brussels, Belgium.</nlm:aff></affiliation></author><author><name sortKey="Van Cutsem, Eric" sort="Van Cutsem, Eric" uniqKey="Van Cutsem E" first="Eric" last="Van Cutsem">Eric Van Cutsem</name><affiliation><nlm:aff id="aff1">From the Department of Radiology, Division of Nuclear Medicine, the Department of Internal Medicine, Division of Endocrinology, and Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of Iowa, Roy J. and Lucille A. Carver College of Medicine; Iowa City Veterans Administration Medical Center, Diagnostic Imaging and Radioisotope Therapy Service, Iowa City, IA; Peter MacCallum Cancer Institute, East Melbourne, Victoria, Australia; Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium; Service de Medecine Nucleaire, Paris; Centre de Médecine Nucleaire, Hospices Civils et Université de Lyon; Institut Gustave Roussy, Villejuif, France; Louisiana State University Health Sciences Center, New Orleans, LA; Division of Hematology-Oncology, Northwestern University, Chicago, IL; Medicinkliniken, Endokrin-Oncol, Uppsala, Sweden; Department of Endocrinology, St Bartholomew's Hospital, London, England; Novartis Pharmaceutical Corporation, East Hanover, NJ; Molecular Insight Pharmaceuticals, Cambridge, MA; and Cliniques Universitaires Saint-Luc, Service de Medecine Nucleaire, Brussels, Belgium.</nlm:aff></affiliation></author><author><name sortKey="Baulieu, Jean Louis" sort="Baulieu, Jean Louis" uniqKey="Baulieu J" first="Jean-Louis" last="Baulieu">Jean-Louis Baulieu</name><affiliation><nlm:aff id="aff1">From the Department of Radiology, Division of Nuclear Medicine, the Department of Internal Medicine, Division of Endocrinology, and Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of Iowa, Roy J. and Lucille A. Carver College of Medicine; Iowa City Veterans Administration Medical Center, Diagnostic Imaging and Radioisotope Therapy Service, Iowa City, IA; Peter MacCallum Cancer Institute, East Melbourne, Victoria, Australia; Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium; Service de Medecine Nucleaire, Paris; Centre de Médecine Nucleaire, Hospices Civils et Université de Lyon; Institut Gustave Roussy, Villejuif, France; Louisiana State University Health Sciences Center, New Orleans, LA; Division of Hematology-Oncology, Northwestern University, Chicago, IL; Medicinkliniken, Endokrin-Oncol, Uppsala, Sweden; Department of Endocrinology, St Bartholomew's Hospital, London, England; Novartis Pharmaceutical Corporation, East Hanover, NJ; Molecular Insight Pharmaceuticals, Cambridge, MA; and Cliniques Universitaires Saint-Luc, Service de Medecine Nucleaire, Brussels, Belgium.</nlm:aff></affiliation></author><author><name sortKey="Borson Chazot, Francoise" sort="Borson Chazot, Francoise" uniqKey="Borson Chazot F" first="Francoise" last="Borson-Chazot">Francoise Borson-Chazot</name><affiliation><nlm:aff id="aff1">From the Department of Radiology, Division of Nuclear Medicine, the Department of Internal Medicine, Division of Endocrinology, and Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of Iowa, Roy J. and Lucille A. Carver College of Medicine; Iowa City Veterans Administration Medical Center, Diagnostic Imaging and Radioisotope Therapy Service, Iowa City, IA; Peter MacCallum Cancer Institute, East Melbourne, Victoria, Australia; Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium; Service de Medecine Nucleaire, Paris; Centre de Médecine Nucleaire, Hospices Civils et Université de Lyon; Institut Gustave Roussy, Villejuif, France; Louisiana State University Health Sciences Center, New Orleans, LA; Division of Hematology-Oncology, Northwestern University, Chicago, IL; Medicinkliniken, Endokrin-Oncol, Uppsala, Sweden; Department of Endocrinology, St Bartholomew's Hospital, London, England; Novartis Pharmaceutical Corporation, East Hanover, NJ; Molecular Insight Pharmaceuticals, Cambridge, MA; and Cliniques Universitaires Saint-Luc, Service de Medecine Nucleaire, Brussels, Belgium.</nlm:aff></affiliation></author><author><name sortKey="Anthony, Lowell" sort="Anthony, Lowell" uniqKey="Anthony L" first="Lowell" last="Anthony">Lowell Anthony</name><affiliation><nlm:aff id="aff1">From the Department of Radiology, Division of Nuclear Medicine, the Department of Internal Medicine, Division of Endocrinology, and Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of Iowa, Roy J. and Lucille A. Carver College of Medicine; Iowa City Veterans Administration Medical Center, Diagnostic Imaging and Radioisotope Therapy Service, Iowa City, IA; Peter MacCallum Cancer Institute, East Melbourne, Victoria, Australia; Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium; Service de Medecine Nucleaire, Paris; Centre de Médecine Nucleaire, Hospices Civils et Université de Lyon; Institut Gustave Roussy, Villejuif, France; Louisiana State University Health Sciences Center, New Orleans, LA; Division of Hematology-Oncology, Northwestern University, Chicago, IL; Medicinkliniken, Endokrin-Oncol, Uppsala, Sweden; Department of Endocrinology, St Bartholomew's Hospital, London, England; Novartis Pharmaceutical Corporation, East Hanover, NJ; Molecular Insight Pharmaceuticals, Cambridge, MA; and Cliniques Universitaires Saint-Luc, Service de Medecine Nucleaire, Brussels, Belgium.</nlm:aff></affiliation></author><author><name sortKey="Benson, Al B" sort="Benson, Al B" uniqKey="Benson A" first="Al B." last="Benson">Al B. Benson</name><affiliation><nlm:aff id="aff1">From the Department of Radiology, Division of Nuclear Medicine, the Department of Internal Medicine, Division of Endocrinology, and Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of Iowa, Roy J. and Lucille A. Carver College of Medicine; Iowa City Veterans Administration Medical Center, Diagnostic Imaging and Radioisotope Therapy Service, Iowa City, IA; Peter MacCallum Cancer Institute, East Melbourne, Victoria, Australia; Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium; Service de Medecine Nucleaire, Paris; Centre de Médecine Nucleaire, Hospices Civils et Université de Lyon; Institut Gustave Roussy, Villejuif, France; Louisiana State University Health Sciences Center, New Orleans, LA; Division of Hematology-Oncology, Northwestern University, Chicago, IL; Medicinkliniken, Endokrin-Oncol, Uppsala, Sweden; Department of Endocrinology, St Bartholomew's Hospital, London, England; Novartis Pharmaceutical Corporation, East Hanover, NJ; Molecular Insight Pharmaceuticals, Cambridge, MA; and Cliniques Universitaires Saint-Luc, Service de Medecine Nucleaire, Brussels, Belgium.</nlm:aff></affiliation></author><author><name sortKey="Oberg, Kjell" sort="Oberg, Kjell" uniqKey="Oberg K" first="Kjell" last="Oberg">Kjell Oberg</name><affiliation><nlm:aff id="aff1">From the Department of Radiology, Division of Nuclear Medicine, the Department of Internal Medicine, Division of Endocrinology, and Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of Iowa, Roy J. and Lucille A. Carver College of Medicine; Iowa City Veterans Administration Medical Center, Diagnostic Imaging and Radioisotope Therapy Service, Iowa City, IA; Peter MacCallum Cancer Institute, East Melbourne, Victoria, Australia; Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium; Service de Medecine Nucleaire, Paris; Centre de Médecine Nucleaire, Hospices Civils et Université de Lyon; Institut Gustave Roussy, Villejuif, France; Louisiana State University Health Sciences Center, New Orleans, LA; Division of Hematology-Oncology, Northwestern University, Chicago, IL; Medicinkliniken, Endokrin-Oncol, Uppsala, Sweden; Department of Endocrinology, St Bartholomew's Hospital, London, England; Novartis Pharmaceutical Corporation, East Hanover, NJ; Molecular Insight Pharmaceuticals, Cambridge, MA; and Cliniques Universitaires Saint-Luc, Service de Medecine Nucleaire, Brussels, Belgium.</nlm:aff></affiliation></author><author><name sortKey="Grossman, Ashley B" sort="Grossman, Ashley B" uniqKey="Grossman A" first="Ashley B." last="Grossman">Ashley B. Grossman</name><affiliation><nlm:aff id="aff1">From the Department of Radiology, Division of Nuclear Medicine, the Department of Internal Medicine, Division of Endocrinology, and Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of Iowa, Roy J. and Lucille A. Carver College of Medicine; Iowa City Veterans Administration Medical Center, Diagnostic Imaging and Radioisotope Therapy Service, Iowa City, IA; Peter MacCallum Cancer Institute, East Melbourne, Victoria, Australia; Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium; Service de Medecine Nucleaire, Paris; Centre de Médecine Nucleaire, Hospices Civils et Université de Lyon; Institut Gustave Roussy, Villejuif, France; Louisiana State University Health Sciences Center, New Orleans, LA; Division of Hematology-Oncology, Northwestern University, Chicago, IL; Medicinkliniken, Endokrin-Oncol, Uppsala, Sweden; Department of Endocrinology, St Bartholomew's Hospital, London, England; Novartis Pharmaceutical Corporation, East Hanover, NJ; Molecular Insight Pharmaceuticals, Cambridge, MA; and Cliniques Universitaires Saint-Luc, Service de Medecine Nucleaire, Brussels, Belgium.</nlm:aff></affiliation></author><author><name sortKey="Connolly, Mary" sort="Connolly, Mary" uniqKey="Connolly M" first="Mary" last="Connolly">Mary Connolly</name><affiliation><nlm:aff id="aff1">From the Department of Radiology, Division of Nuclear Medicine, the Department of Internal Medicine, Division of Endocrinology, and Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of Iowa, Roy J. and Lucille A. Carver College of Medicine; Iowa City Veterans Administration Medical Center, Diagnostic Imaging and Radioisotope Therapy Service, Iowa City, IA; Peter MacCallum Cancer Institute, East Melbourne, Victoria, Australia; Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium; Service de Medecine Nucleaire, Paris; Centre de Médecine Nucleaire, Hospices Civils et Université de Lyon; Institut Gustave Roussy, Villejuif, France; Louisiana State University Health Sciences Center, New Orleans, LA; Division of Hematology-Oncology, Northwestern University, Chicago, IL; Medicinkliniken, Endokrin-Oncol, Uppsala, Sweden; Department of Endocrinology, St Bartholomew's Hospital, London, England; Novartis Pharmaceutical Corporation, East Hanover, NJ; Molecular Insight Pharmaceuticals, Cambridge, MA; and Cliniques Universitaires Saint-Luc, Service de Medecine Nucleaire, Brussels, Belgium.</nlm:aff></affiliation></author><author><name sortKey="Bouterfa, Hakim" sort="Bouterfa, Hakim" uniqKey="Bouterfa H" first="Hakim" last="Bouterfa">Hakim Bouterfa</name><affiliation><nlm:aff id="aff1">From the Department of Radiology, Division of Nuclear Medicine, the Department of Internal Medicine, Division of Endocrinology, and Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of Iowa, Roy J. and Lucille A. Carver College of Medicine; Iowa City Veterans Administration Medical Center, Diagnostic Imaging and Radioisotope Therapy Service, Iowa City, IA; Peter MacCallum Cancer Institute, East Melbourne, Victoria, Australia; Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium; Service de Medecine Nucleaire, Paris; Centre de Médecine Nucleaire, Hospices Civils et Université de Lyon; Institut Gustave Roussy, Villejuif, France; Louisiana State University Health Sciences Center, New Orleans, LA; Division of Hematology-Oncology, Northwestern University, Chicago, IL; Medicinkliniken, Endokrin-Oncol, Uppsala, Sweden; Department of Endocrinology, St Bartholomew's Hospital, London, England; Novartis Pharmaceutical Corporation, East Hanover, NJ; Molecular Insight Pharmaceuticals, Cambridge, MA; and Cliniques Universitaires Saint-Luc, Service de Medecine Nucleaire, Brussels, Belgium.</nlm:aff></affiliation></author><author><name sortKey="Li, Yong" sort="Li, Yong" uniqKey="Li Y" first="Yong" last="Li">Yong Li</name><affiliation><nlm:aff id="aff1">From the Department of Radiology, Division of Nuclear Medicine, the Department of Internal Medicine, Division of Endocrinology, and Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of Iowa, Roy J. and Lucille A. Carver College of Medicine; Iowa City Veterans Administration Medical Center, Diagnostic Imaging and Radioisotope Therapy Service, Iowa City, IA; Peter MacCallum Cancer Institute, East Melbourne, Victoria, Australia; Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium; Service de Medecine Nucleaire, Paris; Centre de Médecine Nucleaire, Hospices Civils et Université de Lyon; Institut Gustave Roussy, Villejuif, France; Louisiana State University Health Sciences Center, New Orleans, LA; Division of Hematology-Oncology, Northwestern University, Chicago, IL; Medicinkliniken, Endokrin-Oncol, Uppsala, Sweden; Department of Endocrinology, St Bartholomew's Hospital, London, England; Novartis Pharmaceutical Corporation, East Hanover, NJ; Molecular Insight Pharmaceuticals, Cambridge, MA; and Cliniques Universitaires Saint-Luc, Service de Medecine Nucleaire, Brussels, Belgium.</nlm:aff></affiliation></author><author><name sortKey="Kacena, Katherine A" sort="Kacena, Katherine A" uniqKey="Kacena K" first="Katherine A." last="Kacena">Katherine A. Kacena</name><affiliation><nlm:aff id="aff1">From the Department of Radiology, Division of Nuclear Medicine, the Department of Internal Medicine, Division of Endocrinology, and Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of Iowa, Roy J. and Lucille A. Carver College of Medicine; Iowa City Veterans Administration Medical Center, Diagnostic Imaging and Radioisotope Therapy Service, Iowa City, IA; Peter MacCallum Cancer Institute, East Melbourne, Victoria, Australia; Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium; Service de Medecine Nucleaire, Paris; Centre de Médecine Nucleaire, Hospices Civils et Université de Lyon; Institut Gustave Roussy, Villejuif, France; Louisiana State University Health Sciences Center, New Orleans, LA; Division of Hematology-Oncology, Northwestern University, Chicago, IL; Medicinkliniken, Endokrin-Oncol, Uppsala, Sweden; Department of Endocrinology, St Bartholomew's Hospital, London, England; Novartis Pharmaceutical Corporation, East Hanover, NJ; Molecular Insight Pharmaceuticals, Cambridge, MA; and Cliniques Universitaires Saint-Luc, Service de Medecine Nucleaire, Brussels, Belgium.</nlm:aff></affiliation></author><author><name sortKey="Lafrance, Norman" sort="Lafrance, Norman" uniqKey="Lafrance N" first="Norman" last="Lafrance">Norman Lafrance</name><affiliation><nlm:aff id="aff1">From the Department of Radiology, Division of Nuclear Medicine, the Department of Internal Medicine, Division of Endocrinology, and Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of Iowa, Roy J. and Lucille A. Carver College of Medicine; Iowa City Veterans Administration Medical Center, Diagnostic Imaging and Radioisotope Therapy Service, Iowa City, IA; Peter MacCallum Cancer Institute, East Melbourne, Victoria, Australia; Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium; Service de Medecine Nucleaire, Paris; Centre de Médecine Nucleaire, Hospices Civils et Université de Lyon; Institut Gustave Roussy, Villejuif, France; Louisiana State University Health Sciences Center, New Orleans, LA; Division of Hematology-Oncology, Northwestern University, Chicago, IL; Medicinkliniken, Endokrin-Oncol, Uppsala, Sweden; Department of Endocrinology, St Bartholomew's Hospital, London, England; Novartis Pharmaceutical Corporation, East Hanover, NJ; Molecular Insight Pharmaceuticals, Cambridge, MA; and Cliniques Universitaires Saint-Luc, Service de Medecine Nucleaire, Brussels, Belgium.</nlm:aff></affiliation></author><author><name sortKey="Pauwels, Stanislas A" sort="Pauwels, Stanislas A" uniqKey="Pauwels S" first="Stanislas A." last="Pauwels">Stanislas A. Pauwels</name><affiliation><nlm:aff id="aff1">From the Department of Radiology, Division of Nuclear Medicine, the Department of Internal Medicine, Division of Endocrinology, and Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of Iowa, Roy J. and Lucille A. Carver College of Medicine; Iowa City Veterans Administration Medical Center, Diagnostic Imaging and Radioisotope Therapy Service, Iowa City, IA; Peter MacCallum Cancer Institute, East Melbourne, Victoria, Australia; Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium; Service de Medecine Nucleaire, Paris; Centre de Médecine Nucleaire, Hospices Civils et Université de Lyon; Institut Gustave Roussy, Villejuif, France; Louisiana State University Health Sciences Center, New Orleans, LA; Division of Hematology-Oncology, Northwestern University, Chicago, IL; Medicinkliniken, Endokrin-Oncol, Uppsala, Sweden; Department of Endocrinology, St Bartholomew's Hospital, London, England; Novartis Pharmaceutical Corporation, East Hanover, NJ; Molecular Insight Pharmaceuticals, Cambridge, MA; and Cliniques Universitaires Saint-Luc, Service de Medecine Nucleaire, Brussels, Belgium.</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">20194865</idno><idno type="pmc">4872330</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872330</idno><idno type="RBID">PMC:4872330</idno><idno type="doi">10.1200/JCO.2009.22.8585</idno><date when="2010">2010</date><idno type="wicri:Area/Pmc/Corpus">000449</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000449</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main"><sup>90</sup>Y-Edotreotide for Metastatic Carcinoid Refractory to Octreotide</title><author><name sortKey="Bushnell, David L" sort="Bushnell, David L" uniqKey="Bushnell D" first="David L." last="Bushnell">David L. Bushnell</name><affiliation><nlm:aff id="aff1">From the Department of Radiology, Division of Nuclear Medicine, the Department of Internal Medicine, Division of Endocrinology, and Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of Iowa, Roy J. and Lucille A. Carver College of Medicine; Iowa City Veterans Administration Medical Center, Diagnostic Imaging and Radioisotope Therapy Service, Iowa City, IA; Peter MacCallum Cancer Institute, East Melbourne, Victoria, Australia; Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium; Service de Medecine Nucleaire, Paris; Centre de Médecine Nucleaire, Hospices Civils et Université de Lyon; Institut Gustave Roussy, Villejuif, France; Louisiana State University Health Sciences Center, New Orleans, LA; Division of Hematology-Oncology, Northwestern University, Chicago, IL; Medicinkliniken, Endokrin-Oncol, Uppsala, Sweden; Department of Endocrinology, St Bartholomew's Hospital, London, England; Novartis Pharmaceutical Corporation, East Hanover, NJ; Molecular Insight Pharmaceuticals, Cambridge, MA; and Cliniques Universitaires Saint-Luc, Service de Medecine Nucleaire, Brussels, Belgium.</nlm:aff></affiliation></author><author><name sortKey="O Dorisio, Thomas M" sort="O Dorisio, Thomas M" uniqKey="O Dorisio T" first="Thomas M." last="O'Dorisio">Thomas M. O'Dorisio</name><affiliation><nlm:aff id="aff1">From the Department of Radiology, Division of Nuclear Medicine, the Department of Internal Medicine, Division of Endocrinology, and Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of Iowa, Roy J. and Lucille A. Carver College of Medicine; Iowa City Veterans Administration Medical Center, Diagnostic Imaging and Radioisotope Therapy Service, Iowa City, IA; Peter MacCallum Cancer Institute, East Melbourne, Victoria, Australia; Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium; Service de Medecine Nucleaire, Paris; Centre de Médecine Nucleaire, Hospices Civils et Université de Lyon; Institut Gustave Roussy, Villejuif, France; Louisiana State University Health Sciences Center, New Orleans, LA; Division of Hematology-Oncology, Northwestern University, Chicago, IL; Medicinkliniken, Endokrin-Oncol, Uppsala, Sweden; Department of Endocrinology, St Bartholomew's Hospital, London, England; Novartis Pharmaceutical Corporation, East Hanover, NJ; Molecular Insight Pharmaceuticals, Cambridge, MA; and Cliniques Universitaires Saint-Luc, Service de Medecine Nucleaire, Brussels, Belgium.</nlm:aff></affiliation></author><author><name sortKey="O Dorisio, M Sue" sort="O Dorisio, M Sue" uniqKey="O Dorisio M" first="M. Sue" last="O'Dorisio">M. Sue O'Dorisio</name><affiliation><nlm:aff id="aff1">From the Department of Radiology, Division of Nuclear Medicine, the Department of Internal Medicine, Division of Endocrinology, and Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of Iowa, Roy J. and Lucille A. Carver College of Medicine; Iowa City Veterans Administration Medical Center, Diagnostic Imaging and Radioisotope Therapy Service, Iowa City, IA; Peter MacCallum Cancer Institute, East Melbourne, Victoria, Australia; Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium; Service de Medecine Nucleaire, Paris; Centre de Médecine Nucleaire, Hospices Civils et Université de Lyon; Institut Gustave Roussy, Villejuif, France; Louisiana State University Health Sciences Center, New Orleans, LA; Division of Hematology-Oncology, Northwestern University, Chicago, IL; Medicinkliniken, Endokrin-Oncol, Uppsala, Sweden; Department of Endocrinology, St Bartholomew's Hospital, London, England; Novartis Pharmaceutical Corporation, East Hanover, NJ; Molecular Insight Pharmaceuticals, Cambridge, MA; and Cliniques Universitaires Saint-Luc, Service de Medecine Nucleaire, Brussels, Belgium.</nlm:aff></affiliation></author><author><name sortKey="Menda, Yusuf" sort="Menda, Yusuf" uniqKey="Menda Y" first="Yusuf" last="Menda">Yusuf Menda</name><affiliation><nlm:aff id="aff1">From the Department of Radiology, Division of Nuclear Medicine, the Department of Internal Medicine, Division of Endocrinology, and Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of Iowa, Roy J. and Lucille A. Carver College of Medicine; Iowa City Veterans Administration Medical Center, Diagnostic Imaging and Radioisotope Therapy Service, Iowa City, IA; Peter MacCallum Cancer Institute, East Melbourne, Victoria, Australia; Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium; Service de Medecine Nucleaire, Paris; Centre de Médecine Nucleaire, Hospices Civils et Université de Lyon; Institut Gustave Roussy, Villejuif, France; Louisiana State University Health Sciences Center, New Orleans, LA; Division of Hematology-Oncology, Northwestern University, Chicago, IL; Medicinkliniken, Endokrin-Oncol, Uppsala, Sweden; Department of Endocrinology, St Bartholomew's Hospital, London, England; Novartis Pharmaceutical Corporation, East Hanover, NJ; Molecular Insight Pharmaceuticals, Cambridge, MA; and Cliniques Universitaires Saint-Luc, Service de Medecine Nucleaire, Brussels, Belgium.</nlm:aff></affiliation></author><author><name sortKey="Hicks, Rodney J" sort="Hicks, Rodney J" uniqKey="Hicks R" first="Rodney J." last="Hicks">Rodney J. Hicks</name><affiliation><nlm:aff id="aff1">From the Department of Radiology, Division of Nuclear Medicine, the Department of Internal Medicine, Division of Endocrinology, and Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of Iowa, Roy J. and Lucille A. Carver College of Medicine; Iowa City Veterans Administration Medical Center, Diagnostic Imaging and Radioisotope Therapy Service, Iowa City, IA; Peter MacCallum Cancer Institute, East Melbourne, Victoria, Australia; Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium; Service de Medecine Nucleaire, Paris; Centre de Médecine Nucleaire, Hospices Civils et Université de Lyon; Institut Gustave Roussy, Villejuif, France; Louisiana State University Health Sciences Center, New Orleans, LA; Division of Hematology-Oncology, Northwestern University, Chicago, IL; Medicinkliniken, Endokrin-Oncol, Uppsala, Sweden; Department of Endocrinology, St Bartholomew's Hospital, London, England; Novartis Pharmaceutical Corporation, East Hanover, NJ; Molecular Insight Pharmaceuticals, Cambridge, MA; and Cliniques Universitaires Saint-Luc, Service de Medecine Nucleaire, Brussels, Belgium.</nlm:aff></affiliation></author><author><name sortKey="Van Cutsem, Eric" sort="Van Cutsem, Eric" uniqKey="Van Cutsem E" first="Eric" last="Van Cutsem">Eric Van Cutsem</name><affiliation><nlm:aff id="aff1">From the Department of Radiology, Division of Nuclear Medicine, the Department of Internal Medicine, Division of Endocrinology, and Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of Iowa, Roy J. and Lucille A. Carver College of Medicine; Iowa City Veterans Administration Medical Center, Diagnostic Imaging and Radioisotope Therapy Service, Iowa City, IA; Peter MacCallum Cancer Institute, East Melbourne, Victoria, Australia; Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium; Service de Medecine Nucleaire, Paris; Centre de Médecine Nucleaire, Hospices Civils et Université de Lyon; Institut Gustave Roussy, Villejuif, France; Louisiana State University Health Sciences Center, New Orleans, LA; Division of Hematology-Oncology, Northwestern University, Chicago, IL; Medicinkliniken, Endokrin-Oncol, Uppsala, Sweden; Department of Endocrinology, St Bartholomew's Hospital, London, England; Novartis Pharmaceutical Corporation, East Hanover, NJ; Molecular Insight Pharmaceuticals, Cambridge, MA; and Cliniques Universitaires Saint-Luc, Service de Medecine Nucleaire, Brussels, Belgium.</nlm:aff></affiliation></author><author><name sortKey="Baulieu, Jean Louis" sort="Baulieu, Jean Louis" uniqKey="Baulieu J" first="Jean-Louis" last="Baulieu">Jean-Louis Baulieu</name><affiliation><nlm:aff id="aff1">From the Department of Radiology, Division of Nuclear Medicine, the Department of Internal Medicine, Division of Endocrinology, and Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of Iowa, Roy J. and Lucille A. Carver College of Medicine; Iowa City Veterans Administration Medical Center, Diagnostic Imaging and Radioisotope Therapy Service, Iowa City, IA; Peter MacCallum Cancer Institute, East Melbourne, Victoria, Australia; Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium; Service de Medecine Nucleaire, Paris; Centre de Médecine Nucleaire, Hospices Civils et Université de Lyon; Institut Gustave Roussy, Villejuif, France; Louisiana State University Health Sciences Center, New Orleans, LA; Division of Hematology-Oncology, Northwestern University, Chicago, IL; Medicinkliniken, Endokrin-Oncol, Uppsala, Sweden; Department of Endocrinology, St Bartholomew's Hospital, London, England; Novartis Pharmaceutical Corporation, East Hanover, NJ; Molecular Insight Pharmaceuticals, Cambridge, MA; and Cliniques Universitaires Saint-Luc, Service de Medecine Nucleaire, Brussels, Belgium.</nlm:aff></affiliation></author><author><name sortKey="Borson Chazot, Francoise" sort="Borson Chazot, Francoise" uniqKey="Borson Chazot F" first="Francoise" last="Borson-Chazot">Francoise Borson-Chazot</name><affiliation><nlm:aff id="aff1">From the Department of Radiology, Division of Nuclear Medicine, the Department of Internal Medicine, Division of Endocrinology, and Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of Iowa, Roy J. and Lucille A. Carver College of Medicine; Iowa City Veterans Administration Medical Center, Diagnostic Imaging and Radioisotope Therapy Service, Iowa City, IA; Peter MacCallum Cancer Institute, East Melbourne, Victoria, Australia; Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium; Service de Medecine Nucleaire, Paris; Centre de Médecine Nucleaire, Hospices Civils et Université de Lyon; Institut Gustave Roussy, Villejuif, France; Louisiana State University Health Sciences Center, New Orleans, LA; Division of Hematology-Oncology, Northwestern University, Chicago, IL; Medicinkliniken, Endokrin-Oncol, Uppsala, Sweden; Department of Endocrinology, St Bartholomew's Hospital, London, England; Novartis Pharmaceutical Corporation, East Hanover, NJ; Molecular Insight Pharmaceuticals, Cambridge, MA; and Cliniques Universitaires Saint-Luc, Service de Medecine Nucleaire, Brussels, Belgium.</nlm:aff></affiliation></author><author><name sortKey="Anthony, Lowell" sort="Anthony, Lowell" uniqKey="Anthony L" first="Lowell" last="Anthony">Lowell Anthony</name><affiliation><nlm:aff id="aff1">From the Department of Radiology, Division of Nuclear Medicine, the Department of Internal Medicine, Division of Endocrinology, and Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of Iowa, Roy J. and Lucille A. Carver College of Medicine; Iowa City Veterans Administration Medical Center, Diagnostic Imaging and Radioisotope Therapy Service, Iowa City, IA; Peter MacCallum Cancer Institute, East Melbourne, Victoria, Australia; Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium; Service de Medecine Nucleaire, Paris; Centre de Médecine Nucleaire, Hospices Civils et Université de Lyon; Institut Gustave Roussy, Villejuif, France; Louisiana State University Health Sciences Center, New Orleans, LA; Division of Hematology-Oncology, Northwestern University, Chicago, IL; Medicinkliniken, Endokrin-Oncol, Uppsala, Sweden; Department of Endocrinology, St Bartholomew's Hospital, London, England; Novartis Pharmaceutical Corporation, East Hanover, NJ; Molecular Insight Pharmaceuticals, Cambridge, MA; and Cliniques Universitaires Saint-Luc, Service de Medecine Nucleaire, Brussels, Belgium.</nlm:aff></affiliation></author><author><name sortKey="Benson, Al B" sort="Benson, Al B" uniqKey="Benson A" first="Al B." last="Benson">Al B. Benson</name><affiliation><nlm:aff id="aff1">From the Department of Radiology, Division of Nuclear Medicine, the Department of Internal Medicine, Division of Endocrinology, and Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of Iowa, Roy J. and Lucille A. Carver College of Medicine; Iowa City Veterans Administration Medical Center, Diagnostic Imaging and Radioisotope Therapy Service, Iowa City, IA; Peter MacCallum Cancer Institute, East Melbourne, Victoria, Australia; Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium; Service de Medecine Nucleaire, Paris; Centre de Médecine Nucleaire, Hospices Civils et Université de Lyon; Institut Gustave Roussy, Villejuif, France; Louisiana State University Health Sciences Center, New Orleans, LA; Division of Hematology-Oncology, Northwestern University, Chicago, IL; Medicinkliniken, Endokrin-Oncol, Uppsala, Sweden; Department of Endocrinology, St Bartholomew's Hospital, London, England; Novartis Pharmaceutical Corporation, East Hanover, NJ; Molecular Insight Pharmaceuticals, Cambridge, MA; and Cliniques Universitaires Saint-Luc, Service de Medecine Nucleaire, Brussels, Belgium.</nlm:aff></affiliation></author><author><name sortKey="Oberg, Kjell" sort="Oberg, Kjell" uniqKey="Oberg K" first="Kjell" last="Oberg">Kjell Oberg</name><affiliation><nlm:aff id="aff1">From the Department of Radiology, Division of Nuclear Medicine, the Department of Internal Medicine, Division of Endocrinology, and Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of Iowa, Roy J. and Lucille A. Carver College of Medicine; Iowa City Veterans Administration Medical Center, Diagnostic Imaging and Radioisotope Therapy Service, Iowa City, IA; Peter MacCallum Cancer Institute, East Melbourne, Victoria, Australia; Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium; Service de Medecine Nucleaire, Paris; Centre de Médecine Nucleaire, Hospices Civils et Université de Lyon; Institut Gustave Roussy, Villejuif, France; Louisiana State University Health Sciences Center, New Orleans, LA; Division of Hematology-Oncology, Northwestern University, Chicago, IL; Medicinkliniken, Endokrin-Oncol, Uppsala, Sweden; Department of Endocrinology, St Bartholomew's Hospital, London, England; Novartis Pharmaceutical Corporation, East Hanover, NJ; Molecular Insight Pharmaceuticals, Cambridge, MA; and Cliniques Universitaires Saint-Luc, Service de Medecine Nucleaire, Brussels, Belgium.</nlm:aff></affiliation></author><author><name sortKey="Grossman, Ashley B" sort="Grossman, Ashley B" uniqKey="Grossman A" first="Ashley B." last="Grossman">Ashley B. Grossman</name><affiliation><nlm:aff id="aff1">From the Department of Radiology, Division of Nuclear Medicine, the Department of Internal Medicine, Division of Endocrinology, and Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of Iowa, Roy J. and Lucille A. Carver College of Medicine; Iowa City Veterans Administration Medical Center, Diagnostic Imaging and Radioisotope Therapy Service, Iowa City, IA; Peter MacCallum Cancer Institute, East Melbourne, Victoria, Australia; Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium; Service de Medecine Nucleaire, Paris; Centre de Médecine Nucleaire, Hospices Civils et Université de Lyon; Institut Gustave Roussy, Villejuif, France; Louisiana State University Health Sciences Center, New Orleans, LA; Division of Hematology-Oncology, Northwestern University, Chicago, IL; Medicinkliniken, Endokrin-Oncol, Uppsala, Sweden; Department of Endocrinology, St Bartholomew's Hospital, London, England; Novartis Pharmaceutical Corporation, East Hanover, NJ; Molecular Insight Pharmaceuticals, Cambridge, MA; and Cliniques Universitaires Saint-Luc, Service de Medecine Nucleaire, Brussels, Belgium.</nlm:aff></affiliation></author><author><name sortKey="Connolly, Mary" sort="Connolly, Mary" uniqKey="Connolly M" first="Mary" last="Connolly">Mary Connolly</name><affiliation><nlm:aff id="aff1">From the Department of Radiology, Division of Nuclear Medicine, the Department of Internal Medicine, Division of Endocrinology, and Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of Iowa, Roy J. and Lucille A. Carver College of Medicine; Iowa City Veterans Administration Medical Center, Diagnostic Imaging and Radioisotope Therapy Service, Iowa City, IA; Peter MacCallum Cancer Institute, East Melbourne, Victoria, Australia; Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium; Service de Medecine Nucleaire, Paris; Centre de Médecine Nucleaire, Hospices Civils et Université de Lyon; Institut Gustave Roussy, Villejuif, France; Louisiana State University Health Sciences Center, New Orleans, LA; Division of Hematology-Oncology, Northwestern University, Chicago, IL; Medicinkliniken, Endokrin-Oncol, Uppsala, Sweden; Department of Endocrinology, St Bartholomew's Hospital, London, England; Novartis Pharmaceutical Corporation, East Hanover, NJ; Molecular Insight Pharmaceuticals, Cambridge, MA; and Cliniques Universitaires Saint-Luc, Service de Medecine Nucleaire, Brussels, Belgium.</nlm:aff></affiliation></author><author><name sortKey="Bouterfa, Hakim" sort="Bouterfa, Hakim" uniqKey="Bouterfa H" first="Hakim" last="Bouterfa">Hakim Bouterfa</name><affiliation><nlm:aff id="aff1">From the Department of Radiology, Division of Nuclear Medicine, the Department of Internal Medicine, Division of Endocrinology, and Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of Iowa, Roy J. and Lucille A. Carver College of Medicine; Iowa City Veterans Administration Medical Center, Diagnostic Imaging and Radioisotope Therapy Service, Iowa City, IA; Peter MacCallum Cancer Institute, East Melbourne, Victoria, Australia; Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium; Service de Medecine Nucleaire, Paris; Centre de Médecine Nucleaire, Hospices Civils et Université de Lyon; Institut Gustave Roussy, Villejuif, France; Louisiana State University Health Sciences Center, New Orleans, LA; Division of Hematology-Oncology, Northwestern University, Chicago, IL; Medicinkliniken, Endokrin-Oncol, Uppsala, Sweden; Department of Endocrinology, St Bartholomew's Hospital, London, England; Novartis Pharmaceutical Corporation, East Hanover, NJ; Molecular Insight Pharmaceuticals, Cambridge, MA; and Cliniques Universitaires Saint-Luc, Service de Medecine Nucleaire, Brussels, Belgium.</nlm:aff></affiliation></author><author><name sortKey="Li, Yong" sort="Li, Yong" uniqKey="Li Y" first="Yong" last="Li">Yong Li</name><affiliation><nlm:aff id="aff1">From the Department of Radiology, Division of Nuclear Medicine, the Department of Internal Medicine, Division of Endocrinology, and Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of Iowa, Roy J. and Lucille A. Carver College of Medicine; Iowa City Veterans Administration Medical Center, Diagnostic Imaging and Radioisotope Therapy Service, Iowa City, IA; Peter MacCallum Cancer Institute, East Melbourne, Victoria, Australia; Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium; Service de Medecine Nucleaire, Paris; Centre de Médecine Nucleaire, Hospices Civils et Université de Lyon; Institut Gustave Roussy, Villejuif, France; Louisiana State University Health Sciences Center, New Orleans, LA; Division of Hematology-Oncology, Northwestern University, Chicago, IL; Medicinkliniken, Endokrin-Oncol, Uppsala, Sweden; Department of Endocrinology, St Bartholomew's Hospital, London, England; Novartis Pharmaceutical Corporation, East Hanover, NJ; Molecular Insight Pharmaceuticals, Cambridge, MA; and Cliniques Universitaires Saint-Luc, Service de Medecine Nucleaire, Brussels, Belgium.</nlm:aff></affiliation></author><author><name sortKey="Kacena, Katherine A" sort="Kacena, Katherine A" uniqKey="Kacena K" first="Katherine A." last="Kacena">Katherine A. Kacena</name><affiliation><nlm:aff id="aff1">From the Department of Radiology, Division of Nuclear Medicine, the Department of Internal Medicine, Division of Endocrinology, and Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of Iowa, Roy J. and Lucille A. Carver College of Medicine; Iowa City Veterans Administration Medical Center, Diagnostic Imaging and Radioisotope Therapy Service, Iowa City, IA; Peter MacCallum Cancer Institute, East Melbourne, Victoria, Australia; Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium; Service de Medecine Nucleaire, Paris; Centre de Médecine Nucleaire, Hospices Civils et Université de Lyon; Institut Gustave Roussy, Villejuif, France; Louisiana State University Health Sciences Center, New Orleans, LA; Division of Hematology-Oncology, Northwestern University, Chicago, IL; Medicinkliniken, Endokrin-Oncol, Uppsala, Sweden; Department of Endocrinology, St Bartholomew's Hospital, London, England; Novartis Pharmaceutical Corporation, East Hanover, NJ; Molecular Insight Pharmaceuticals, Cambridge, MA; and Cliniques Universitaires Saint-Luc, Service de Medecine Nucleaire, Brussels, Belgium.</nlm:aff></affiliation></author><author><name sortKey="Lafrance, Norman" sort="Lafrance, Norman" uniqKey="Lafrance N" first="Norman" last="Lafrance">Norman Lafrance</name><affiliation><nlm:aff id="aff1">From the Department of Radiology, Division of Nuclear Medicine, the Department of Internal Medicine, Division of Endocrinology, and Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of Iowa, Roy J. and Lucille A. Carver College of Medicine; Iowa City Veterans Administration Medical Center, Diagnostic Imaging and Radioisotope Therapy Service, Iowa City, IA; Peter MacCallum Cancer Institute, East Melbourne, Victoria, Australia; Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium; Service de Medecine Nucleaire, Paris; Centre de Médecine Nucleaire, Hospices Civils et Université de Lyon; Institut Gustave Roussy, Villejuif, France; Louisiana State University Health Sciences Center, New Orleans, LA; Division of Hematology-Oncology, Northwestern University, Chicago, IL; Medicinkliniken, Endokrin-Oncol, Uppsala, Sweden; Department of Endocrinology, St Bartholomew's Hospital, London, England; Novartis Pharmaceutical Corporation, East Hanover, NJ; Molecular Insight Pharmaceuticals, Cambridge, MA; and Cliniques Universitaires Saint-Luc, Service de Medecine Nucleaire, Brussels, Belgium.</nlm:aff></affiliation></author><author><name sortKey="Pauwels, Stanislas A" sort="Pauwels, Stanislas A" uniqKey="Pauwels S" first="Stanislas A." last="Pauwels">Stanislas A. Pauwels</name><affiliation><nlm:aff id="aff1">From the Department of Radiology, Division of Nuclear Medicine, the Department of Internal Medicine, Division of Endocrinology, and Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of Iowa, Roy J. and Lucille A. Carver College of Medicine; Iowa City Veterans Administration Medical Center, Diagnostic Imaging and Radioisotope Therapy Service, Iowa City, IA; Peter MacCallum Cancer Institute, East Melbourne, Victoria, Australia; Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium; Service de Medecine Nucleaire, Paris; Centre de Médecine Nucleaire, Hospices Civils et Université de Lyon; Institut Gustave Roussy, Villejuif, France; Louisiana State University Health Sciences Center, New Orleans, LA; Division of Hematology-Oncology, Northwestern University, Chicago, IL; Medicinkliniken, Endokrin-Oncol, Uppsala, Sweden; Department of Endocrinology, St Bartholomew's Hospital, London, England; Novartis Pharmaceutical Corporation, East Hanover, NJ; Molecular Insight Pharmaceuticals, Cambridge, MA; and Cliniques Universitaires Saint-Luc, Service de Medecine Nucleaire, Brussels, Belgium.</nlm:aff></affiliation></author></analytic><series><title level="j">Journal of Clinical Oncology</title><idno type="ISSN">0732-183X</idno><idno type="eISSN">1527-7755</idno><imprint><date when="2010">2010</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><sec><title>Purpose</title><p>Metastatic carcinoid is an incurable malignancy whose symptoms, such as diarrhea and flushing, can be debilitating and occasionally life-threatening. Although symptom relief is available with octreotide, the disease eventually becomes refractory to octreotide, leaving no proven treatment options. The goal of this study was to evaluate the clinical effect of using <sup>90</sup>Y-edotreotide to treat symptomatic patients with carcinoid tumors.</p></sec><sec><title>Patients and Methods</title><p>Patients enrolled had metastatic carcinoid, at least one sign/symptom refractory to octreotide, and at least one measurable lesion. Study treatment consisted of three cycles of 4.4 GBq (120 mCi) <sup>90</sup>Y-edotreotide each, once every 6 weeks.</p></sec><sec><title>Results</title><p>Ninety patients were enrolled in the study. Using Southwest Oncology Group tumor response criteria, 67 (74.%) of 90 patients (95% CI, 65.4% to 83.4%) were objectively stable or responded. A statistically significant linear trend toward improvement was demonstrated across all 12 symptoms assessed. Median progression-free survival was significantly greater (<italic>P</italic> = .03) for the 38 patients who had durable diarrhea improvement than the 18 patients who did not (18.2 <italic>v</italic> 7.9 months, respectively). Adverse events (AEs) were reported in 96.7% (87 of 90) of patients. These AEs consisted primarily of reversible GI events (76 of 90), which could be caused in part by concomitant administration of amino acid solution given to reduce radiation exposure to the kidneys. There was one case each of grade 3 oliguria and grade 4 renal failure, each lasting 6 days.</p></sec><sec><title>Conclusion</title><p><sup>90</sup>Y-edotreotide treatment improved symptoms associated with malignant carcinoid among subjects with no treatment alternatives. Treatment was well-tolerated and had an acceptable expected AE profile.</p></sec></div></front></TEI><pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front><journal-meta><journal-id journal-id-type="nlm-ta">J Clin Oncol</journal-id><journal-id journal-id-type="iso-abbrev">J. Clin. Oncol</journal-id><journal-id journal-id-type="hwp">jco</journal-id><journal-id journal-id-type="pmc">jco</journal-id><journal-id journal-id-type="publisher-id">JCO</journal-id><journal-title-group><journal-title>Journal of Clinical Oncology</journal-title></journal-title-group><issn pub-type="ppub">0732-183X</issn><issn pub-type="epub">1527-7755</issn><publisher><publisher-name>American Society of Clinical Oncology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">20194865</article-id><article-id pub-id-type="pmc">4872330</article-id><article-id pub-id-type="publisher-id">28585</article-id><article-id pub-id-type="doi">10.1200/JCO.2009.22.8585</article-id><article-categories><subj-group subj-group-type="collcodes"><subject>Endo4</subject><subject>Endo7</subject><subject>Gic32</subject><subject>Gic35</subject></subj-group><subj-group subj-group-type="heading"><subject>ORIGINAL REPORTS</subject><subj-group><subject>Gastrointestinal Cancer</subject></subj-group></subj-group></article-categories><title-group><article-title><sup>90</sup>Y-Edotreotide for Metastatic Carcinoid Refractory to Octreotide</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Bushnell</surname><given-names>David L.</given-names><suffix>Jr</suffix></name><xref ref-type="aff" rid="aff1"></xref><xref ref-type="corresp" rid="cor1"></xref></contrib><contrib contrib-type="author"><name><surname>O'Dorisio</surname><given-names>Thomas M.</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>O'Dorisio</surname><given-names>M. Sue</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Menda</surname><given-names>Yusuf</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Hicks</surname><given-names>Rodney J.</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Van Cutsem</surname><given-names>Eric</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Baulieu</surname><given-names>Jean-Louis</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Borson-Chazot</surname><given-names>Francoise</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Anthony</surname><given-names>Lowell</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Benson</surname><given-names>Al B.</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Oberg</surname><given-names>Kjell</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Grossman</surname><given-names>Ashley B.</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Connolly</surname><given-names>Mary</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Bouterfa</surname><given-names>Hakim</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Yong</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Kacena</surname><given-names>Katherine A.</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>LaFrance</surname><given-names>Norman</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Pauwels</surname><given-names>Stanislas A.</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><aff id="aff1">From the Department of Radiology, Division of Nuclear Medicine, the Department of Internal Medicine, Division of Endocrinology, and Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of Iowa, Roy J. and Lucille A. Carver College of Medicine; Iowa City Veterans Administration Medical Center, Diagnostic Imaging and Radioisotope Therapy Service, Iowa City, IA; Peter MacCallum Cancer Institute, East Melbourne, Victoria, Australia; Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium; Service de Medecine Nucleaire, Paris; Centre de Médecine Nucleaire, Hospices Civils et Université de Lyon; Institut Gustave Roussy, Villejuif, France; Louisiana State University Health Sciences Center, New Orleans, LA; Division of Hematology-Oncology, Northwestern University, Chicago, IL; Medicinkliniken, Endokrin-Oncol, Uppsala, Sweden; Department of Endocrinology, St Bartholomew's Hospital, London, England; Novartis Pharmaceutical Corporation, East Hanover, NJ; Molecular Insight Pharmaceuticals, Cambridge, MA; and Cliniques Universitaires Saint-Luc, Service de Medecine Nucleaire, Brussels, Belgium.</aff></contrib-group><author-notes><corresp id="cor1">Corresponding author: David L. Bushnell, MD, Department of Radiology, University of Iowa Roy J. and Lucille A. Carver College of Medicine, 200 Hawkins Dr, Iowa City, IA 52242; e-mail: <email>david-bushnell@uiowa.edu</email>.</corresp></author-notes><pub-date pub-type="ppub"><day>1</day><month>4</month><year>2010</year></pub-date><pub-date pub-type="epub"><day>1</day><month>3</month><year>2010</year></pub-date><pub-date pub-type="pmc-release"><day>1</day><month>3</month><year>2010</year></pub-date><pmc-comment> PMC Release delay is 0 months and 0 days and was based on the
<volume>28</volume><issue>10</issue><fpage>1652</fpage><lpage>1659</lpage><history><date date-type="received"><day>23</day><month>3</month><year>2009</year></date><date date-type="accepted"><day>9</day><month>12</month><year>2009</year></date></history><permissions><copyright-statement>© 2010 by American Society of Clinical Oncology</copyright-statement><copyright-year>2010</copyright-year></permissions><self-uri xlink:title="pdf" xlink:type="simple" xlink:href="zlj01010001652.pdf"></self-uri><abstract><sec><title>Purpose</title><p>Metastatic carcinoid is an incurable malignancy whose symptoms, such as diarrhea and flushing, can be debilitating and occasionally life-threatening. Although symptom relief is available with octreotide, the disease eventually becomes refractory to octreotide, leaving no proven treatment options. The goal of this study was to evaluate the clinical effect of using <sup>90</sup>Y-edotreotide to treat symptomatic patients with carcinoid tumors.</p></sec><sec><title>Patients and Methods</title><p>Patients enrolled had metastatic carcinoid, at least one sign/symptom refractory to octreotide, and at least one measurable lesion. Study treatment consisted of three cycles of 4.4 GBq (120 mCi) <sup>90</sup>Y-edotreotide each, once every 6 weeks.</p></sec><sec><title>Results</title><p>Ninety patients were enrolled in the study. Using Southwest Oncology Group tumor response criteria, 67 (74.%) of 90 patients (95% CI, 65.4% to 83.4%) were objectively stable or responded. A statistically significant linear trend toward improvement was demonstrated across all 12 symptoms assessed. Median progression-free survival was significantly greater (<italic>P</italic> = .03) for the 38 patients who had durable diarrhea improvement than the 18 patients who did not (18.2 <italic>v</italic> 7.9 months, respectively). Adverse events (AEs) were reported in 96.7% (87 of 90) of patients. These AEs consisted primarily of reversible GI events (76 of 90), which could be caused in part by concomitant administration of amino acid solution given to reduce radiation exposure to the kidneys. There was one case each of grade 3 oliguria and grade 4 renal failure, each lasting 6 days.</p></sec><sec><title>Conclusion</title><p><sup>90</sup>Y-edotreotide treatment improved symptoms associated with malignant carcinoid among subjects with no treatment alternatives. Treatment was well-tolerated and had an acceptable expected AE profile.</p></sec></abstract></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000449 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000449 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé=
|texte=
}}
| This area was generated with Dilib version V0.6.33. |  |